Results 31 to 40 of about 219,778 (281)

An updated review on activated PI3 kinase delta syndrome (APDS)

Genes and Diseases, 2020
Activated Phosphoinositide 3-kinase δ syndrome (APDS) is a newly recognised primary immunodeficiency disease. It has currently been a hot topic of clinical research and new data are emerging regarding its pathogenesis, clinical manifestations and ...
Ankita Singh, Vibhu Joshi, Ankur Kumar Jindal, Babu Mathew, Amit Rawat   +4 more
doaj   +1 more source

Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors [PDF]

ACS Medicinal Chemistry Letters, 2010
Phospoinositide-3-kinases (PI3K) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. A series of 2-morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inhibitors of PI3Ks. Herein, we describe the structure-guided optimization of these pyrimidines with a
Matthew T, Burger, Mark, Knapp, Allan, Wagman, Zhi-Jie, Ni, Thomas, Hendrickson, Gordana, Atallah, Yanchen, Zhang, Kelly, Frazier, Joelle, Verhagen, Keith, Pfister, Simon, Ng, Aaron, Smith, Sarah, Bartulis, Hanne, Merrit, Marion, Weismann, Xiaohua, Xin, Joshua, Haznedar, Charles F, Voliva, Ed, Iwanowicz, Sabina, Pecchi   +19 more
openaire   +2 more sources

Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase [PDF]

Trends in Pharmacological Sciences, 2013
Phosphoinositide (PI) 3-kinases are essential regulators of cellular proliferation, survival, metabolism, and motility that are frequently dysregulated in human disease. The design of inhibitors to target the PI 3-kinase/mTOR pathway is a major area of investigation by both academic laboratories and the pharmaceutical industry.
Hashem A, Dbouk, Jonathan M, Backer
openaire   +2 more sources

Immunodeficiency due to a novel variant in PIK3CD: a case report

Pediatric Rheumatology Online Journal, 2023
Background Primary immunodeficiencies are immunological disorders caused by gene mutations involved in immune system development and activation. Recently, activated phosphoinositide 3-kinase delta syndrome (APDS) due to mutations in the phosphoinositide ...
Niloofar Shashaani, Zahra Chavoshzadeh, Leila Ghasemi, Shabnam Hajiani Ghotbabadi, Sara Shiari, Samin Sharafian, Reza Shiari   +6 more
doaj   +1 more source

Overview of Research into mTOR Inhibitors

Molecules, 2022
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family.
Beibei Mao, Qi Zhang, Li Ma, Dong-Sheng Zhao, Pan Zhao, Peizheng Yan   +5 more
doaj   +1 more source

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

Haematologica, 2014
The phosphoinositide 3-kinase pathway represents an important anticancer target because it has been implicated in cancer cell growth, survival, and motility. Recent studies show that PI3K may also play a role in the development of resistance to currently
Elias Jabbour, Oliver G. Ottmann, Michael Deininger, Andreas Hochhaus   +3 more
doaj   +1 more source

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers

Zhongliu Fangzhi Yanjiu, 2019
Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR ...
ZHANG Baihong, YUE Hongyun
doaj   +1 more source

The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation

Tumor Biology, 2017
In this study, we investigated the underlying mechanism of the phosphoinositide 3-kinase/Akt– and Wnt/β-catenin-mediated promotion of epithelial-to-mesenchymal transition by epigenetic regulation of histone acetylation in gastric cancer.
Yue Song, Zhao-xia Li, Xi Liu, Rui Wang, Li-wei Li, Qingyu Zhang   +5 more
doaj   +1 more source

The Treatment of Activated PI3Kδ Syndrome

Frontiers in Immunology, 2018
Activated phosphoinositide 3-kinase δ syndrome (APDS), also known as PASLI disease (p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency) are combined immunodeficiencies resulting from gain-of-function mutations in ...
Tanya I. Coulter, Andrew J. Cant
doaj   +1 more source

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

PLoS ONE, 2017
Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui, Sarah A Meadows, Rick A Sorensen, Zhi-Hua Cui, Kathleen S Keegan, Robert Brockett, Guang Chen, Christophe Quéva, Li Li, Stacey L Tannheimer   +9 more
doaj   +1 more source